What are your top takeaways in Hematologic Malignancies from ASCO 2023?

1. S1826 - Randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). AAVD vs. NAVD for advanced stage Hodgkin. Just when we thought outcomes couldn’t get much better, this study showed the superiority of Nivolumab over Brentuximab Vedotin when paired with AVD chemotherapy. Longer follow-up is needed, but likely to be practice-changing.
2. A041702 - Results of a phase 3 study of IVO vs IO for previously untreated older patients (patie...

1. SWOG 1826 - cHL study; immediately applicable to patients with cHL > 60
2. ZUMA-7 - OS advantage for 2nd line CAR-T; should lessen barrier to referral to CAR-T
3. POLARIX - Pola R-CHP can safely deliver to advanced-age DLBCL patients; the definition for trial in such a population should be carefully scrutinized.

1. A+AVD vs. N+AVD:
1. Head to head study that looks like it has established a new SOC for patients with advanced stage HL given the improvement in PFS and improved toxicity profile. This is monumental given that just recently A+AVD recently established itself as a SOC with the demonstration of a OS benefit compared to ABVD.
2. Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.
1. Study originally looked at R maintenanc...

The presentation linking Agent Orange to MPNs was very interesting. My veteran patients often ask me about this and now we have the first study that shows increased rates of bleeding, thrombosis as well as the risk of developing an MPN with Agent Orange exposure. The zilurgisertib and luspatercept studies were also interesting- Cytopenias have not been well addressed by current therapies so knowing that luspatercept has efficacy in MF is wonderful news. It's also encouraging to see other agents ...

Here are my top 3 acute leukemia abstracts from ASCO 2023:

1. Abstract 7000 by Roddie and others: Top-line results of a pivotal phase Ib/II study of obecabtagene autoleucel (obe-cel), a new CD19-targeted CAR-T cell product for adults with relapsed/refractory B-ALL. Unlike other iterations of CAR-T cells, this product uses a novel CD19 binding domain with a “fast-off rate.” The hope is that this would lead to altered T-cell activation kinetics, generating less exhaustion and better persistence. Thi...

The top three lymphoma abstracts were:

1. LBA4: SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)
   The study demonstrates early superiority of nivolumab AVD compared to BV-AVD but also improved toxicity in advanced stage Hodgkin lymphoma in kids and adults. This will become the new standard of care in this population likely.
   
   
2. LBA107: Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of a...